core/shell quantum dots (QDs) can be used as stable and highly active photoredoxcatalysts for efficient transferhydrogenation of imines to amines with thiophenol as a hydrogen atom donor. This reaction proceeds via a proton-coupled electron transfer (PCET) from the QDs conduction band to the protonated imine followed by hydrogen atom transfer from the thiophenol to the α-aminoalkyl radical. This precious
Ruthenium N‐Heterocyclic Carbene Complexes for Chemoselective Reduction of Imines and Reductive Amination of Aldehydes and Ketones
作者:Lakshay Kathuria、Ashoka G. Samuelson
DOI:10.1002/ejic.202000069
日期:2020.6.30
Chemoselective reduction of imines to secondary amines is catalyzed efficiently by tethered and untethered, half‐sandwich ruthenium N‐heterocyclic carbene (NHC) complexes at room temperature. The untethered Ru‐NHC complexes are more efficient as catalysts for the reduction of aldimines and ketimines than the tethered complexes. Using the best untethered complex as a catalyst, electronic and steric
Reduction of imines catalysed by NHC substituted group 6 metal carbonyls
作者:Noor U Din Reshi、Lakshay Kathuria、Ashoka G. Samuelson
DOI:10.1016/j.ica.2018.10.026
日期:2019.2
Abstract The catalytic activity of a series of metalcarbonyls [M(CO)6], and the corresponding NHC substituted [M(CO)5(NHC)], (M = Cr, Mo, W) complexes was examined in the reduction of N-benzylideneaniline and acetophenone using silyl hydrides and isopropanol/KOH as reductants. The use of various additives and ultraviolet irradiation to promote the reduction of imines using silyl hydrides as reductants
Novel amide derivatives and medicinal use thereof ugs
申请人:——
公开号:US20040138223A1
公开(公告)日:2004-07-15
The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action
1
wherein each symbol is as defined in the specification.
The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.
The present invention relates to an amide derivative of the formula (1), having a C5a receptor antagonistic action
wherein each symbol is as defined in the specification.
The above-mentioned amide derivative, an optically active form thereof and a pharmaceutically acceptable salt thereof are promising as an agent for the treatment or prophylaxis of diseases or syndromes caused by inflammation caused by C5a [e.g., autoimmune diseases such as rheumatism, systemic lupus erythematosus and the like, sepsis, adult respiratory distress syndrome, chronic obstructive pulmonary disease, allergic diseases such as asthma and the like, atherosclerosis, cardiac infarction, brain infarction, psoriasis, Alzheimer's disease and serious organ injury (e.g., pneumonia, nephritis, hepatitis and pancreatitis and the like) due to activation of leukocytes caused by ischemia reperfusion, trauma, burn, surgical invasion and the like]. Moreover, they are useful as a therapeutic or prophylactic agent for the infectious diseases caused by bacteria and virus that invade via a C5a receptor.